Tagged with S

Hungary MD Pál Szamosújvari, Judit Jávor, Pál Szamosújvari Jr—Founder, R&D Director, and Director of Pharma Patent respectively—share their insights on the activities of the company, the importance of R&D, the challenges of smaller companies, its marketing strategy of its niche products, and its internationalization strategy.   Can you introduce yourself and…

Czech Republic Ewopharma’s Jan Krejčí, Country Manager for the Czech affiliate for the last eight years, shares the achievements of the company in its two main business pillars, prescription drugs, and consumer healthcare, and the successful entry into the hospital segment through the challenging and rewarding journey launching Santhera’s orphan drug for…

Czech Republic Miha Kline has been with Eli Lilly for the past 15 years, becoming Country Manager Czech Republic and Slovakia four years ago. Kline shares his milestones with the affiliate successfully entering new therapeutic areas and reaching 1bn CZK in sales. Kline also discusses the challenging market access conditions and the…

Hungary Csilla Léka, general manager of Global Clinical Trials in Hungary shares her insights on the portfolio of the company, the most prevalent therapeutic areas, the developments in clinical trials over the last decade, and her outlook on the future of the company.   In comparison with Western European countries, Hungary…

China Dr Yuguang Wang, CEO of Maxinovel Pharmaceuticals, recaps his three decades of industry experience across Big Pharma, biotech and CRO organizations in China and the US, his motivation to establish Maxinovel Pharmaceuticals as a global, semi-virtual biotech, and their mission to develop a pipeline of orally-active one-pill combination of immuno-oncology…

Hungary Calin Galaseanu, recently appointed general manager of Novo Nordisk Hungary, elaborates on the country’s strong treatment paradigm for diabetes. He goes on to highlight Hungary’s key positioning as a strategic affiliate for Novo Nordisk in the areas of market access success and clinical trial capabilities.     Hungary is actually…

UAE Vishnu Kalra, Janssen’s managing director for the GCC region, reflects on his 18-year career with Johnson & Johnson, including his perspective on the success factors behind the company’s strong growth in the region. Moreover, he highlights Janssen’s diversified portfolio across different therapeutic areas, with neuroscience, oncology, haematology, pulmonary arterial hypertension…

Hungary László Dene, managing director of Bellis, gives his insights on the trends affecting the wholesale supply chain and product delivery in Hungary, the strategic positioning of the company as the subsidiary of Hungaropharma – the country’s largest wholesaler – specialized in OTC healthcare products and the importance of their newly…

USA In 2019 big pharma companies prioritised shareholder payouts and dividends, with the eight biggest US pharma companies topping $31 billion in stock buybacks and the same amount in dividends. Revenues were not necessarily consistent with dividend and buyback amounts, and some critics argue that payouts should be lessened in favour…

China 2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating biotech and biotech-related firms, mostly originating from mainland China, listing last year. The average amount of funds raised by these was a whopping four to five times higher…

Opinion Health Catalyst’s Elia Stupka explains why and how patients must be kept at the centre of the healthcare systems of the future, even as they become increasingly data-driven.   Healthcare data is seen by many as the ‘new goldmine,’ with many businesses in this field evaluated and sold at a significant…

Hungary Gergely Jánoki CEO of Medi-Radiopharma shares his insights on the activities of the company, the trends in the radiopharmaceutical industry while highlighting regulatory trends, the importance of quality, the driving factors behind the company’s success and his long-term vision of for the company.   We grew more than 60 percent…